213 related articles for article (PubMed ID: 21949869)
21. Grb10 is involved in BCR-ABL-positive leukemia in mice.
Illert AL; Albers C; Kreutmair S; Leischner H; Peschel C; Miething C; Duyster J
Leukemia; 2015 Apr; 29(4):858-68. PubMed ID: 25249015
[TBL] [Abstract][Full Text] [Related]
22. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms.
Dai Y; Rahmani M; Pei XY; Dent P; Grant S
Blood; 2004 Jul; 104(2):509-18. PubMed ID: 15039284
[TBL] [Abstract][Full Text] [Related]
23. Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis.
Yuan H; Wang Z; Li L; Zhang H; Modi H; Horne D; Bhatia R; Chen W
Blood; 2012 Feb; 119(8):1904-14. PubMed ID: 22207735
[TBL] [Abstract][Full Text] [Related]
24. Antileukemia effects of xanthohumol in Bcr/Abl-transformed cells involve nuclear factor-kappaB and p53 modulation.
Monteghirfo S; Tosetti F; Ambrosini C; Stigliani S; Pozzi S; Frassoni F; Fassina G; Soverini S; Albini A; Ferrari N
Mol Cancer Ther; 2008 Sep; 7(9):2692-702. PubMed ID: 18790751
[TBL] [Abstract][Full Text] [Related]
25. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
Burchert A; Wang Y; Cai D; von Bubnoff N; Paschka P; Müller-Brüsselbach S; Ottmann OG; Duyster J; Hochhaus A; Neubauer A
Leukemia; 2005 Oct; 19(10):1774-82. PubMed ID: 16136169
[TBL] [Abstract][Full Text] [Related]
26. Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib.
Griswold IJ; MacPartlin M; Bumm T; Goss VL; O'Hare T; Lee KA; Corbin AS; Stoffregen EP; Smith C; Johnson K; Moseson EM; Wood LJ; Polakiewicz RD; Druker BJ; Deininger MW
Mol Cell Biol; 2006 Aug; 26(16):6082-93. PubMed ID: 16880519
[TBL] [Abstract][Full Text] [Related]
27. BCR-ABL gene expression is required for its mutations in a novel KCL-22 cell culture model for acquired resistance of chronic myelogenous leukemia.
Yuan H; Wang Z; Gao C; Chen W; Huang Q; Yee JK; Bhatia R; Chen W
J Biol Chem; 2010 Feb; 285(7):5085-96. PubMed ID: 20007699
[TBL] [Abstract][Full Text] [Related]
28. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
Rahmani M; Nguyen TK; Dent P; Grant S
Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328
[TBL] [Abstract][Full Text] [Related]
29. Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL--expressing cells, demonstrating synergy between AG490 and STI571.
Sun X; Layton JE; Elefanty A; Lieschke GJ
Blood; 2001 Apr; 97(7):2008-15. PubMed ID: 11264165
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of the PI3K/Akt/GSK3 pathway downstream of BCR/ABL, Jak2-V617F, or FLT3-ITD downregulates DNA damage-induced Chk1 activation as well as G2/M arrest and prominently enhances induction of apoptosis.
Kurosu T; Nagao T; Wu N; Oshikawa G; Miura O
PLoS One; 2013; 8(11):e79478. PubMed ID: 24260231
[TBL] [Abstract][Full Text] [Related]
31. Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells.
Essafi A; Fernández de Mattos S; Hassen YA; Soeiro I; Mufti GJ; Thomas NS; Medema RH; Lam EW
Oncogene; 2005 Mar; 24(14):2317-29. PubMed ID: 15688014
[TBL] [Abstract][Full Text] [Related]
32. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS
Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571).
Wohlbold L; van der Kuip H; Miething C; Vornlocher HP; Knabbe C; Duyster J; Aulitzky WE
Blood; 2003 Sep; 102(6):2236-9. PubMed ID: 12750174
[TBL] [Abstract][Full Text] [Related]
34. Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells.
Carter BZ; Mak DH; Schober WD; Cabreira-Hansen M; Beran M; McQueen T; Chen W; Andreeff M
Blood; 2006 Feb; 107(4):1555-63. PubMed ID: 16254145
[TBL] [Abstract][Full Text] [Related]
35. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.
Scappini B; Gatto S; Onida F; Ricci C; Divoky V; Wierda WG; Andreeff M; Dong L; Hayes K; Verstovsek S; Kantarjian HM; Beran M
Cancer; 2004 Apr; 100(7):1459-71. PubMed ID: 15042680
[TBL] [Abstract][Full Text] [Related]
36. In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia.
La Rosée P; Johnson K; O'Dwyer ME; Druker BJ
Exp Hematol; 2002 Jul; 30(7):729-37. PubMed ID: 12135670
[TBL] [Abstract][Full Text] [Related]
37. Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells.
Reddiconto G; Toto C; Palamà I; De Leo S; de Luca E; De Matteis S; Dini L; Passerini CG; Di Renzo N; Maffia M; Coluccia AM
Blood; 2012 Mar; 119(10):2335-45. PubMed ID: 22262776
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.
Salizzato V; Borgo C; Cesaro L; Pinna LA; Donella-Deana A
Oncotarget; 2016 Apr; 7(14):18204-18. PubMed ID: 26919095
[TBL] [Abstract][Full Text] [Related]
39. PECAM-1 is involved in BCR/ABL signaling and may downregulate imatinib-induced apoptosis of Philadelphia chromosome-positive leukemia cells.
Wu N; Kurosu T; Oshikawa G; Nagao T; Miura O
Int J Oncol; 2013 Feb; 42(2):419-28. PubMed ID: 23233201
[TBL] [Abstract][Full Text] [Related]
40. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.
Aichberger KJ; Mayerhofer M; Krauth MT; Skvara H; Florian S; Sonneck K; Akgul C; Derdak S; Pickl WF; Wacheck V; Selzer E; Monia BP; Moriggl R; Valent P; Sillaber C
Blood; 2005 Apr; 105(8):3303-11. PubMed ID: 15626746
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
